Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Ocera Therapeutics, Inc. | oceraannouncessuccessfulph.htm |
| EX-99.1 - EXHIBIT 99.1 - Ocera Therapeutics, Inc. | ocerapresentationjanuary.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 5, 2017
OCERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
(Exact name of registrant as specified in its charter)
DELAWARE | 001-35119 | 63-1192270 | ||
(State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
of | Identification No.) | |||
incorporation) | ||||
Registrant’s telephone number, including area code (650) 475-0150
525 University Avenue, Suite 610 | ||
Palo Alto, CA | 94301 | |
(Address of principal executive offices) | (Zip Code) | |
Not Applicable
(Former name or former address, if changed since last report)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Other Events.
The management of Ocera Therapeutics, Inc. (the “Company”) will participate in investor meetings at the 35th Annual J.P. Morgan Healthcare Conference beginning on Monday, January 9, 2017 in San Francisco. A copy of the presentation slide deck to be used in conjunction with the investor meetings is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On January 5, 2017, the Company issued a press release announcing the results of its Phase 1 clinical study of orally-administered OCR-002 in patients with cirrhosis. The full text of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Ocera Therapeutics, Inc. Presentation Slide Deck. | |
99.2 | Press release issued by Ocera Therapeutics, Inc. dated January 5, 2017. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
January 9, 2017 | Ocera Therapeutics, Inc. | ||
By: | /s/ Linda S. Grais, M.D. | ||
Name: Linda S. Grais, M.D. | |||
Title: President and Chief Executive Officer | |||
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | Ocera Therapeutics, Inc. Presentation Slide Deck. | |
99.2 | Press release issued by Ocera Therapeutics, Inc. dated January 5, 2017. | |